The inducer of differentiation of human promyelocytic leukemia HL-60 cells is commonly accepted to have potential therapeutic importance. Verticinone, one of the major isosteroidal alkaloids from the bulbus of Fritillaria ussuriensis, was found to inhibit the growth of HL-60 cells by inducing these cells to differentiate toward granulocytes. Importantly, the combination of verticinone with all-trans retinoic acid (ATRA), a well-known inducer of HL-60 cells into granulocytic lineages, was more effective than either alone, suggesting its therapeutic use in minimizing the effective dose of ATRA.
The inducer of differentiation of human promyelocytic leukemia HL-60 cells is commonly accepted to have potential therapeutic importance. All-trans retinoic acid (ATRA) is a potent inducer of the granulocytic differentiation of HL-60 cells and has been used to treat acute promyelocytic leukemia.
1) The therapeutic actions, however, are short-lived and accompanied by a variety of side effects.
2) Thus it is desirable to discover new inducers of HL-60 cell differentiation with fewer side effects and/or nontoxic agents to minimize the effective dose of ATRA.
Bulbus Fritillariae (Chinese name, Beimu), derived from the bulbs of various species of the genus Fritillaria (Liliaceae), has been used as an antitussive and expectorant in traditional Chinese medicine.
3) It is well documented that the major constituents in Beimu are isosteroidal alkaloids. 4, 5) Verticine and verticinone ( Fig. 1) are the major alkaloids in commonly used Fritillaria herbs. 4, 5) Other alkaloids, including isoverticine (Fig. 1) , ebeiedine, and ebeiedinone, have been also isolated from various Fritillaria species. 4, 5) Although it has been reported that verticinone possesses an antitussive effect 6) and antitumor activity, 7) to the best of our knowledge there has been no report on the differentiation-inducing activity of verticinone. Here we report that verticinone is able to inhibit the in vitro growth of HL-60 cells and induce the granulocytic differentiation of the cells.
MATERIALS AND METHODS
General NMR spectra were recorded in acetone-d 6 Extraction and Isolation Dried bulbs of F. ussuriensis (500 g) were extracted with MeOH (6 l) for 24 h. The MeOH extract was concentrated, suspended in H 2 O, and sequentially partitioned with n-hexane, EtOAc, and BuOH. The BuOH fraction (fr.) (3.9 g) was subjected to octadecyl functionalized silica gel flash-column (2.5ϫ40 cm) chromatography. The column was eluted with a stepwise gradient with 250-ml aliquots of MeOH in H 2 O (from 20 to 100% in 10% increments), followed by 300 ml of 50% MeOH in CH 2 fraction eluted between 385 ml and 532 ml (87.2 mg) was then further purified by chromatography on a silica gel column (3.0ϫ5.0 cm; 63-200 mm particle size) chromatography eluted with CHCl 3 -MeOH-NH(Et) 2 (13 : 1 : 0.2) to afford verticinone (1, 8.0 mg, R f ϭ0.4). The fraction eluted between 533 ml and 630 ml (103.5 mg) was then further purified by chromatography on a silica gel column (3.0ϫ5 cm; 63-200 mm particle size) chromatography eluted with EtOAc-CHCl 3 -NH(Et) 2 (8 : 2 : 0.5) to afford isoverticine (2, 10.5 mg, R f ϭ0.3).
The structures of compounds 1 and 2 were identified by the comparison of spectral properties (MS, 1 H-, and 13 C-NMR) with those reported in the literature. 8, 9) Cell Cultures The human myeloid leukemia cell lines HL-60, NB4, and U937 were cultured in suspension in RPMI 1640 medium (Life Technologies, MD, U.S.A.) supplemented with 10% fetal bovine serum (GIBCO BRL, Grand Island, NY, U.S.A.) at 37°C in a humidified atmosphere of 5% CO 2 in air.
Growth-Inhibitory Assay The cell number was counted using a model Z1 Coulter Counter (Beckman Coulter Electronics, Luton, U.K.), and cell viability was confirmed by the ability of cells to exclude Trypan blue dye (Sigma Chemical, St. Louis, MO, U.S.A.). Cellular proliferation was determined by the method using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Chemical) as described previously. 10) Briefly, 10 ml of MTT (5 mg/ml) was added to each well of 96-well plates containing 2ϫ10 5 cells after treatment with different concentrations of verticinone or isoverticine for 3 d. The reaction was stopped after 4-h incubation by adding 100 ml of 0.04 N HCl in isopropanol, and the optical density at 570 nm was determined with a microcolorimetric reader.
Differentiation Asaay Differentiation was determined by the nitroblue tetrazolium (NBT) (Sigma Chemical) reduction assay with some modifications as previously reported. 10) Briefly, cells were incubated with verticinone or ATRA (Sigma Chemical) in 96-well plates (2ϫ10 5 cells/well) for 4 d. Then the cells were resuspended in 200 ml of RPMI-1640 medium containing 2 mg/ml of NBT and 1 mg/ml of 12-Otetradecanoylphorbol 13-acetate (Sigma Chemical). After incubation at 37°C for 30 min, the cells were centrifuged and resuspended in 100 ml of phosphate-buffered saline. They were then smeared on a glass slide and counterstained with 0.3% (w/v) safranin O (Sigma Chemical) in methanol. Positive cells reduce NBT, yielding intracellular deposits of black-blue formazan dye; this ability was determined by the microscopic examination of over 200 cells. Morphologic differentiation was examined in cell smears stained with Wright-Giemsa. 10) Expression of CD11b and CD14 was analyzed by indirect immunofluorescent staining and flow cytometry using FACS Vantage as described elsewhere. 10) 
RESULTS AND DISCUSSION
In the MTT and Trypan blue dye-exclusion assays against human myelogenous leukemia cell lines including HL-60 cells, verticinone inhibited cell growth but did not induce cell death (Table 1) , while isoverticine was inactive. This suggests that the ketone group of verticinone may play an important role in its growth-inhibitory activity. The growth inhibition of leukemia cells by verticinone is assumed to be associated with terminal differentiation, but not with its cytotoxicity. This effect was verified using the NBT assay to evaluate the functional differentiation of either granulocytes or monocytes on leukemia cells. As shown in Fig. 2 , verticinone increased the number of NBT-positive cells in a time-dependent manner. With respect to its growth-inhibitory and differentiation-inducing effects, HL-60 cells were the most sensitive to verticinone and when the cells were treated with verticinone for more than 4 d, the maximum effect was induced. HL-60 cells can differentiate into granulocytes or monocytes, depending on the inducer used, the maturation profiles of HL-60 cells treated with verticinone were analyzed by morphologic examination using the Wright-Giemsa method. Most of the control cells were myeloblasts (Fig. 3A) , while metamyelocytes and banded neutrophils characteristic of granulocytic differentiation were predominant in verticinonetreated cells (arrowheads in Fig. 3B ). The granulocytic differentiation of HL-60 cells induced by verticinone was also confirmed by the findings that both verticinone and ATRA (a well-known inducer of HL-60 cells into granulocytic lineages) induced the expression of CD11b (myelomonocytic differentiation antigen) but had no effect on the expression of CD14 (monocyte/macrophage antigen) ( Table 2) .
Finally, we examined the effect of the combined use of ATRA and verticinone on the differentiation of HL-60 cells. The combination was more effective than either agent alone (Fig. 4) . The clinical use of ATRA has proven to be partially successful in inducing remissions in patients with acute promyelocytic leukemia. 1, 2) On the other hand, severe side effects, known as retinoic acid syndrome, are often experienced. 1, 2) One approach that has been developed to overcome the severe side effects is to reduce the effective concentration of ATRA in combination with other differentiation inducers.
Since verticinone cooperates with ATRA, the therapeutic use of verticinone with ATRA might be expected to minimize the effective dose of ATRA. The mechanism by which verticinone induces the granulocytic differentiation of HL-60 cells remains to be elucidated. There are many ways to induce differentiation, because the inducers of differentiation act by different mechanisms to induce the production of more or less identical end-stage cells. This may reflect flexibility in the differentiation program. However, there may be common final pathways that mediate maturation in malignant cells by bypassing genetic defects, thus reversing the malignant phenotype.
In conclusion, it was verified from our data that verticinone inhibits the in vitro growth of human myelogenous leukemia cell lines. In particular, this compound appeared to induce the differentiation of HL-60 cells into granulocytic cells, as did ATRA. 
